MX2022013841A - Inhibidores de la interaccion de menina-mll. - Google Patents

Inhibidores de la interaccion de menina-mll.

Info

Publication number
MX2022013841A
MX2022013841A MX2022013841A MX2022013841A MX2022013841A MX 2022013841 A MX2022013841 A MX 2022013841A MX 2022013841 A MX2022013841 A MX 2022013841A MX 2022013841 A MX2022013841 A MX 2022013841A MX 2022013841 A MX2022013841 A MX 2022013841A
Authority
MX
Mexico
Prior art keywords
menin
inhibitors
mll
interaction
mll interaction
Prior art date
Application number
MX2022013841A
Other languages
English (en)
Inventor
Jing Yuan
David A Claremon
Stephen D Lotesta
Chengguo Dong
Yi Fan
Lanqi Jia
Suresh B Singh
Linghang Zhuang
Salvacion Cacatian
Shankar Venkatraman
Yajun Zheng
Original Assignee
Vitae Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vitae Pharmaceuticals Inc filed Critical Vitae Pharmaceuticals Inc
Publication of MX2022013841A publication Critical patent/MX2022013841A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a inhibidores de la interacción de menina con MLL y proteínas de fusión de MLL, composiciones farmacéuticas que las contienen, y su uso en el tratamiento del cáncer y otras enfermedades mediadas por la interacción de menina-MLL.
MX2022013841A 2016-09-16 2019-03-15 Inhibidores de la interaccion de menina-mll. MX2022013841A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662395618P 2016-09-16 2016-09-16

Publications (1)

Publication Number Publication Date
MX2022013841A true MX2022013841A (es) 2022-11-30

Family

ID=59966892

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019003091A MX2019003091A (es) 2016-09-16 2017-09-15 Inhibidores de la interaccion de menina-mll.
MX2022013841A MX2022013841A (es) 2016-09-16 2019-03-15 Inhibidores de la interaccion de menina-mll.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019003091A MX2019003091A (es) 2016-09-16 2017-09-15 Inhibidores de la interaccion de menina-mll.

Country Status (18)

Country Link
US (3) US10899758B2 (es)
EP (2) EP4230627A3 (es)
JP (2) JP2019529421A (es)
KR (1) KR102536029B1 (es)
CN (1) CN110325533A (es)
AR (1) AR109658A1 (es)
AU (1) AU2017326006B2 (es)
BR (1) BR112019005030A2 (es)
CA (1) CA3036987A1 (es)
DK (1) DK3512850T3 (es)
ES (1) ES2948949T3 (es)
FI (1) FI3512850T3 (es)
IL (2) IL265028B (es)
MX (2) MX2019003091A (es)
PL (1) PL3512850T3 (es)
RU (1) RU2019111169A (es)
TW (1) TWI757340B (es)
WO (1) WO2018053267A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016040330A1 (en) 2014-09-09 2016-03-17 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
US10588907B2 (en) 2015-06-04 2020-03-17 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
CN109640987B (zh) 2016-03-16 2022-12-02 库拉肿瘤学公司 Menin-mll的桥联双环抑制剂及使用方法
CN114539284A (zh) 2016-03-16 2022-05-27 库拉肿瘤学公司 经取代的menin-mll抑制剂及使用方法
US10899738B2 (en) 2016-05-02 2021-01-26 The Regents Of The University Of Michigan Piperidines as menin inhibitors
BR112019004764A2 (pt) 2016-09-14 2019-05-28 Janssen Pharmaceutica Nv inibidores bicíclicos fundidos da interação menina-mll
MX2019002962A (es) 2016-09-14 2019-07-04 Janssen Pharmaceutica Nv Inhibidores espirobiciclicos de la interaccion de menina-mll.
CA3036987A1 (en) * 2016-09-16 2018-03-22 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
MX2019007067A (es) 2016-12-15 2019-10-15 Janssen Pharmaceutica Nv Inhibidores de azepano de la interacción menina-mll.
EP3601249A4 (en) 2017-03-24 2020-12-16 Kura Oncology, Inc. METHODS OF TREATMENT OF MALIGNANT HEMOPATHIES AND EWING'S SARCOMA
SG11201909083UA (en) 2017-03-31 2019-10-30 Univ Michigan Regents Piperidines as covalent menin inhibitors
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
EP3684361A4 (en) 2017-09-20 2021-09-08 Kura Oncology, Inc. MENINE-MLL SUBSTITUTE INHIBITORS AND METHODS OF USE
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
WO2019146740A1 (ja) * 2018-01-26 2019-08-01 塩野義製薬株式会社 ドーパミンｄ３受容体拮抗作用を有する環式化合物
JP7239562B2 (ja) 2018-03-30 2023-03-14 住友ファーマ株式会社 光学活性な架橋型環状２級アミン誘導体
EA202190623A1 (ru) * 2018-08-27 2021-05-21 Сумитомо Дайниппон Фарма Ко., Лтд. Оптически активное азабициклическое производное
US20210206765A1 (en) * 2018-09-13 2021-07-08 Kissei Pharmaceutical Co., Ltd. Imidazopyridinone compound
TW202039512A (zh) 2018-12-06 2020-11-01 日商第一三共股份有限公司 環烷-1,3-二胺化合物
KR20220050963A (ko) * 2019-09-20 2022-04-25 노파르티스 아게 Mll1 억제제 및 항암제
WO2021060453A1 (ja) * 2019-09-27 2021-04-01 大日本住友製薬株式会社 架橋型光学活性２級アミン誘導体
JOP20220154A1 (ar) * 2019-12-19 2023-01-30 Janssen Pharmaceutica Nv مشتقات سبيرو بسلسلة مستقيمة بها استبدال
US11091447B2 (en) 2020-01-03 2021-08-17 Berg Llc UBE2K modulators and methods for their use
CN111297863B (zh) * 2020-03-30 2021-06-25 四川大学华西医院 menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用
AR122159A1 (es) * 2020-05-28 2022-08-17 Novartis Ag Inhibidores de mll1 y agentes antineoplásicos
US20240101549A1 (en) 2020-12-17 2024-03-28 Astrazeneca Ab N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides
AU2022272692A1 (en) 2021-05-08 2024-01-04 Janssen Pharmaceutica Nv Substituted spiro derivatives
WO2022237627A1 (en) 2021-05-08 2022-11-17 Janssen Pharmaceutica Nv Substituted spiro derivatives
TW202311262A (zh) 2021-05-14 2023-03-16 美商錫達斯醫藥股份有限公司 Menin-mll交互作用之抑制劑
EP4347588A1 (en) 2021-06-01 2024-04-10 JANSSEN Pharmaceutica NV Substituted phenyl-1h-pyrrolo[2, 3-c]pyridine derivatives
CA3218340A1 (en) 2021-06-03 2022-12-08 Janssen Pharmaceutica Nv Pyridazines or 1,2,4-triazines substituted by spirocyclic amines
WO2022262796A1 (en) 2021-06-17 2022-12-22 Janssen Pharmaceutica Nv (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-m ethylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer
CN116903609A (zh) * 2021-11-05 2023-10-20 上海优理惠生医药有限公司 一种化合物、包含其的药物组合物及其应用
WO2023084320A1 (en) * 2021-11-11 2023-05-19 V-Ensure Pharma Technologies Private Limited Reconstitutable, single use antidiabetic compositions
WO2023193790A1 (en) * 2022-04-08 2023-10-12 Janssen Pharmaceutica Nv Crystalline forms of an inhibitor of the menin/mll interaction
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
WO2024114666A1 (en) * 2022-11-30 2024-06-06 Janssen Pharmaceutica Nv Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor
WO2024114664A1 (en) * 2022-11-30 2024-06-06 Janssen Pharmaceutica Nv Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent
WO2024114658A1 (en) * 2022-11-30 2024-06-06 Janssen Pharmaceutica Nv Substituted 1-phenyl-3, 4-dihydropyrido [3, 4-d] pyrimidin-2-one derivatives
WO2024114662A1 (en) * 2022-11-30 2024-06-06 Janssen Pharmaceutica Nv Cyclobutyl substituted bicyclic compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK3852001A3 (en) * 1998-09-18 2003-03-04 Basf Ag 4-Aminopyrrolopyrimidines as kinase inhibitors
US8859581B2 (en) 2005-04-25 2014-10-14 Merck Patent Gmbh Azaheterocyclic compounds as kinase inhibitors
WO2010066629A2 (en) * 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Novel azaindoles
GB201004311D0 (en) * 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
PL2578585T3 (pl) 2010-05-31 2017-01-31 Ono Pharmaceutical Co., Ltd. Pochodna purynonu jako inhibitor kinazy btk
JP2014532060A (ja) 2011-10-03 2014-12-04 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 癌を治療するためのピロロピリミジン化合物
US8377946B1 (en) * 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
JP6327713B2 (ja) * 2012-07-27 2018-05-23 国立研究開発法人理化学研究所 急性骨髄性白血病の治療又は再発抑制剤
BR112015011171A2 (pt) * 2012-11-15 2017-07-11 Pharmacyclics Inc compostos de pirrolopirimidina como inibidores da quinase
CA2915163A1 (en) * 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
WO2015058084A1 (en) * 2013-10-18 2015-04-23 Medivation Technologies, Inc. Heterocyclic compounds and methods of use
US10278979B2 (en) * 2015-03-11 2019-05-07 Riken Therapeutic agent for intractable leukemia
CA3036987A1 (en) * 2016-09-16 2018-03-22 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction

Also Published As

Publication number Publication date
RU2019111169A (ru) 2020-10-20
IL265028B (en) 2022-09-01
US20190202830A1 (en) 2019-07-04
WO2018053267A1 (en) 2018-03-22
US20210179611A1 (en) 2021-06-17
JP2022189853A (ja) 2022-12-22
AU2017326006B2 (en) 2021-10-28
BR112019005030A2 (pt) 2019-06-18
MX2019003091A (es) 2019-07-08
PL3512850T3 (pl) 2023-10-09
AR109658A1 (es) 2019-01-09
AU2017326006A1 (en) 2019-03-21
EP4230627A2 (en) 2023-08-23
RU2019111169A3 (es) 2020-12-30
EP3512850B1 (en) 2023-04-12
ES2948949T3 (es) 2023-09-22
JP2019529421A (ja) 2019-10-17
IL265028A (es) 2019-04-30
IL295972A (en) 2022-10-01
US10899758B2 (en) 2021-01-26
KR102536029B1 (ko) 2023-05-23
CA3036987A1 (en) 2018-03-22
DK3512850T3 (da) 2023-07-03
EP3512850A1 (en) 2019-07-24
TWI757340B (zh) 2022-03-11
EP4230627A3 (en) 2023-11-15
FI3512850T3 (fi) 2023-06-20
US20240124447A1 (en) 2024-04-18
TW201825486A (zh) 2018-07-16
US11739085B2 (en) 2023-08-29
CN110325533A (zh) 2019-10-11
KR20190111008A (ko) 2019-10-01

Similar Documents

Publication Publication Date Title
MX2022013841A (es) Inhibidores de la interaccion de menina-mll.
MX2021003939A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
MX2018007703A (es) Inhibidores de la interaccion de menina-linaje leucemico mixto.
PH12017501483A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
PH12019502810A1 (en) Bicyclic heterocycles as fgfr inhibitors
PH12018502429A1 (en) Antibody molecules for cancer treatment
PH12017501481A1 (en) Bicyclic heterocycles as fgfr inhibitors
MX2021006531A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201690159A1 (ru) Способы и композиции для лечения рака
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
MX2020000135A (es) Nuevos compuestos de quinolinona.
MX2017009608A (es) Compuestos anticancerigenos.
EA202090270A1 (ru) Новые замещенные производные ксантина
MX2019010218A (es) Derivados de pirazol como inhibidores de bromodominio.
PH12017501693A1 (en) Compositions for the treatment of kidney and/or liver diseases
TW201613926A (en) Inhibitors of bruton's tyrosine kinase
EA202190877A1 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr